Trial Information

Summary: FREEDOMS II - Multiple Sclerosis Study

The purpose of this clinical research study is to find out if an oral once-a-day investigational drug called fingolimod is safe and has beneficial effects in people who have relapsing-remitting Multiple Sclerosis (MS) over a two year period. Fingolimod is an oral once-a-day medicine which has not been approved yet for the treatment of patients with multiple sclerosis and is therefore not "on the market" (available for you to buy) in any country.

14 visits to the study center, over a period of 24 months.
For more information about this clinical trial, visit

This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.

Trial listings updated: September 5, 2008 at 3:14:19 PM